Propranolol Modulates Burn-Induced Metabolic Dysfunction
2026-08-06
Propranolol Modulates Burn-Induced Metabolic Dysfunction
Study Background and Research Question
Severe burns covering over 20% of total body surface area trigger a profound hypermetabolic response, characterized by persistent catabolism, increased resting energy expenditure, and long-term metabolic derangements. This state is largely driven by a surge in endogenous catecholamines, which promote lipolysis, inflammation, and remodeling of adipose tissue. While propranolol, a nonselective beta-adrenergic blocker, is clinically recognized for attenuating these effects and improving outcomes in burn patients, the precise metabolic mechanisms involved have remained unclear. The reference study (Rehou et al., Ann Surg 2023) addresses this knowledge gap, hypothesizing that propranolol exerts its beneficial effects by normalizing metabolomic signatures in adipose tissue.Key Innovation from the Reference Study
The central innovation of this work lies in its detailed characterization of how propranolol modulates metabolic and lipidomic pathways in human adipose tissue following burn injury. Unlike prior studies that focused on clinical endpoints or gross physiological markers, this trial integrates untargeted metabolomics and molecular pathway analysis to reveal propranolol’s impact on core energy and nucleotide metabolism, as well as on the degradation of catecholamines. Additionally, the study links these molecular changes to downstream anti-inflammatory and anti-catabolic outcomes, advancing the mechanistic understanding of beta-blockade in burn care.Methods and Experimental Design Insights
The investigators conducted a phase II randomized controlled trial enrolling 52 patients with acute burns affecting at least 20% of total body surface area. Subjects were allocated to receive either standard care or propranolol titrated to maintain a heart rate below 100 bpm. Adipose tissue samples were analyzed for metabolomic, lipidomic, and molecular pathway alterations. Key endpoints included the quantification of inflammatory lipids, the assessment of lipolytic enzyme activation, markers of endoplasmic reticulum (ER) stress, and clinical outcomes.- Metabolomics: Untargeted profiling was performed on adipose tissue to identify global shifts in energy and nucleotide metabolism.
- Lipidomics: Quantification of proinflammatory and anti-inflammatory fatty acids, with a focus on the ratio of saturated to polyunsaturated fatty acids.
- Molecular Pathways: Western blot and phosphorylation analysis of hormone-sensitive lipase (HSL) and ER stress markers (e.g., phospho-JNK).
- Clinical Metrics: Heart rate, resting energy expenditure, and surrogate markers of catabolism and inflammation.
Protocol Parameters
- Propranolol administration: Dosed to achieve heart rate <100 bpm post-burn; typically initiated within 1–2 days of admission.
- Sample collection: Adipose tissue harvested during clinically indicated procedures in the subacute post-burn period.
- Metabolomic/lipidomic profiling: Untargeted LC-MS/MS with subsequent pathway enrichment analysis.
- ER stress and enzyme activation assays: Immunoblotting for p-JNK and HSL Ser660 phosphorylation.
Core Findings and Why They Matter
The study demonstrates that propranolol significantly remodels the metabolic landscape of adipose tissue after burn injury. Key findings include:- Normalization of energy and nucleotide metabolism pathways: Propranolol reverses burn-induced alterations in core metabolic pathways, suggesting restoration of cellular energy homeostasis (Rehou et al.).
- Lipidomic shift toward anti-inflammatory profile: Treatment decreased proinflammatory palmitic acid and saturated fatty acids, while increasing the polyunsaturated fatty acid ratio—linked to improved inflammatory tone.
- Suppression of lipolysis and ER stress: Decreased activation of hormone-sensitive lipase (notably at Ser660) and reduced phospho-JNK levels indicate dampened lipolytic drive and ER stress, both key contributors to burn-associated catabolic state.
- Clinical improvement: These molecular changes are associated with improved markers of systemic stress and catabolism, providing mechanistic support for propranolol’s clinical efficacy in burn recovery.
Comparison with Existing Internal Articles
Several internal resources provide complementary perspectives on metabolic modulation and energy homeostasis, particularly in mitochondrial research. For example, the article "NADH in Mitochondrial Electron Transport Chain Research" details how reduced nicotinamide adenine dinucleotide (NADH) is central to dissecting mitochondrial function and metabolic regulation. While the reference study focuses on systemic and adipose tissue-level metabolic remodeling after burn injury, internal resources such as "NADH in Mitochondrial Electron Transport Chain Research" and "NADH (Reduced-form Nicotinamide Adenine Dinucleotide) as..." highlight the importance of NADH/NAD⁺ ratio and redox state in disease modeling, including applications in diabetic nephropathy research, Leigh syndrome models, and cancer metabolism. Together, these resources emphasize that robust control of metabolic and redox pathways—whether at the cellular, tissue, or whole-organism scale—is fundamental to understanding stress responses and developing targeted interventions.Limitations and Transferability
Despite its strengths, the reference study’s findings are subject to several limitations:- Patient population: The trial enrolled adults with large burns; extrapolation to pediatric populations or less severe injuries should be approached with caution.
- Tissue specificity: While adipose tissue is a key metabolic organ, burn pathophysiology involves other tissues (muscle, liver) not directly examined here.
- Metabolomics scope: Although untargeted, not all detected metabolites can be definitively linked to clinical endpoints without further validation.
- Intervention window: Early post-burn intervention was studied; effects of delayed propranolol administration remain unclear.